HIV pharmacology: barriers to the eradication of HIV from the CNS

Related Experiment Video

Updated: Aug 6, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Bryan McGee1, Nathalie Smith, Francesca Aweeka

  • 1Drug Research Unit, University of California-San Francisco, 521 Parnassus Avenue, San Francisco, CA 94143, USA.

HIV Clinical Trials
|August 2, 2006
PubMed

Insights

Complete eradication of human immunodeficiency virus type 1 (HIV-1) remains elusive due to latent viral reservoirs in the central nervous system (CNS). HIV-1 in the CNS is linked to HIV dementia, impacting up to 20% of untreated individuals.

Area of Science:

  • Neuroscience
  • Virology
  • Infectious Diseases

Background:

  • Latent human immunodeficiency virus type 1 (HIV-1) reservoirs in lymphoid tissue, testes, and the central nervous system (CNS) impede total eradication.
  • HIV-1 infection in the CNS is a significant clinical concern, associated with the development of HIV dementia in a substantial proportion of untreated patients.

Purpose of the Study:

  • To review current theories on HIV-1 infection within the CNS.
  • To describe factors limiting antiretroviral drug penetration into the CNS.
  • To summarize current treatments for CNS HIV-1 infection and HIV encephalopathy.

Main Methods:

  • Literature review of existing theories and research on HIV-1 CNS infection.
  • Analysis of physiological and pharmacological factors affecting antiretroviral drug CNS penetration.
  • Synthesis of current treatment strategies for CNS HIV-1 and HIV encephalopathy.

Main Results:

  • HIV-1 establishes latent reservoirs in the CNS, contributing to treatment challenges.
  • Physiological barriers and drug properties limit effective antiretroviral therapy delivery to the CNS.
  • Current treatments for CNS HIV-1 infection and HIV encephalopathy are reviewed.

Conclusions:

  • Understanding CNS HIV-1 reservoirs and drug penetration is crucial for developing effective eradication strategies.
  • Further research is needed to optimize antiretroviral therapy for CNS penetration and efficacy.
  • Effective management of HIV-1 in the CNS is essential to prevent neurological complications like HIV dementia.

More Related Videos

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Factors Affecting Drug Distribution: Physiological Barriers01:23

Factors Affecting Drug Distribution: Physiological Barriers

Drug distribution in the body is intricately regulated by various physiological barriers that control the passage of substances. These include the capillary endothelial barrier, the blood-brain, blood-cerebrospinal fluid, blood-placental, and blood-testis barriers.
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...
Physiological Barriers01:25

Physiological Barriers

Physiological barriers are semi-permeable cellular structures restricting drug diffusion into intracellular compartments and tissues. There are six types of physiological barriers: blood endothelial, cell membrane, blood-brain, blood-cerebrospinal fluid (CSF), blood-placenta, and blood-testis barriers.
The blood endothelial barrier is the most porous of these. It allows all small ionized, un-ionized, and lipophilic molecules to pass through the endothelial lining into the interstitial space...